Unveiling Novel Therapeutic Targets for Septic Myocardial Injury: The Role of PIK3CG Recombinant Rabbit Monoclonal Antibodies by ANT BIO PTE. LTD.

1. Concept

Sepsis-induced systemic inflammation often leads to multiple organ dysfunction syndrome, with myocardial injury being a critical factor affecting patient prognosis—septic patients with myocardial dysfunction have a mortality rate of 70%-90%, significantly higher than those without. The pathological mechanisms involve pro-inflammatory cytokine release, calcium homeostasis imbalance, mitochondrial dysfunction, reactive oxygen species overproduction, and activation of cell death pathways (apoptosis, necroptosis, pyroptosis). PIK3CG, encoding the gamma catalytic subunit of phosphatidylinositol 3-kinase (p110γ), is a key member of the PI3K/AKT signaling pathway. It regulates inflammatory responses (neutrophil chemotaxis, macrophage activation, cytokine production) and myocardial cell survival signals (metabolism, proliferation, anti-apoptosis), making it a potential core regulatory gene in septic myocardial injury. PIK3CG recombinant rabbit monoclonal antibodies enable in-depth study of its mechanism and discovery of therapeutic targets.

2. Research Frontiers

A key research frontier focuses on clarifying the dual role of PIK3CG in septic myocardial injury. Researchers are using the antibody to explore whether PIK3CG promotes excessive inflammation while mediating myocardial protection, aiming to develop strategies that selectively modulate its functions.

Another active area of investigation involves optimizing PIK3CG-targeted therapies. Studies show melatonin may bind PIK3CG to exert myocardial protection, and the antibody supports validation of this mechanism and screening of more specific modulators (e.g., small molecules, bispecific antibodies).

Emerging frontiers also include developing PIK3CG as a biomarker. Research is exploring whether its expression or phosphorylation status can assess septic myocardial injury severity or predict treatment response, aiding personalized medicine.

3. Research Significance

PIK3CG recombinant rabbit monoclonal antibodies hold profound significance for septic myocardial injury research and clinical translation. In basic science, they uncover PIK3CG’s role in inflammatory signaling and myocardial cell survival, advancing understanding of disease pathogenesis. This knowledge addresses the lack of effective treatments for septic myocardial injury.

Clinically, the antibody validates PIK3CG as a therapeutic target, supporting development of targeted therapies (e.g., melatonin derivatives, PI3Kγ modulators). It also aids in drug efficacy evaluation and biomarker development, improving patient diagnosis, prognosis, and treatment outcomes.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

PIK3CG (p110γ) exerts dual effects in septic myocardial injury: On the inflammatory side, it activates immune cells (neutrophils, macrophages) to release pro-inflammatory cytokines, amplifying systemic inflammation and myocardial damage. On the myocardial protection side, it mediates PI3K/AKT signaling in cardiomyocytes, promoting survival by inhibiting apoptosis and improving mitochondrial function. As illustrated in the diagram, sepsis disrupts this balance—excessive PIK3CG-driven inflammation outweighs its protective effects. Melatonin may bind PIK3CG to modulate its activity, restoring the balance and reducing myocardial injury.

Research Methods and Product Applications

PIK3CG recombinant rabbit monoclonal antibodies are versatile tools for septic myocardial injury research. ANT BIO PTE. LTD.’s PIK3CG Recombinant Rabbit Monoclonal Antibody (Catalog No.: S0B1448) stands out for its high specificity, broad species reactivity, and multi-application compatibility, making it essential for mechanism studies and drug development.

Key Applications of the Antibody:

• Protein Expression and Localization: Using WB, IHC, and IF, the antibody quantifies PIK3CG expression in myocardial tissues and identifies its subcellular distribution in cardiomyocytes, immune cells, and endothelial cells.
• Signaling Pathway Analysis: It detects PIK3CG phosphorylation and membrane translocation, evaluating PI3K/AKT pathway activation in septic myocardial injury.
• Drug Mechanism Validation: In melatonin or other interventions, the antibody assesses drug effects on PIK3CG expression, activity, and downstream targets.
• Interaction Network Studies: Combined with co-IP and mass spectrometry, it reveals PIK3CG’s interaction proteins in sepsis, mapping regulatory networks.
• Targeted Therapy Evaluation: In PIK3CG-deficient or overexpressing animal models, the antibody validates the target’s role in myocardial protection.

Core Advantages of the Antibody:

• High Specificity: Specifically recognizes PIK3CG (p110γ) with minimal cross-reactivity to other PI3K subunits (p110α/β/δ), ensuring accurate detection.
• Broad Species Reactivity: Cross-reacts with human, mouse, and rat PIK3CG, supporting cross-species research and translational studies.
• Multi-Platform Compatibility: Performs excellently in WB, IP, and IF, enabling comprehensive analysis of protein expression, interactions, and localization.
• Batch Consistency: Produced via recombinant technology, ensuring stable performance across batches for reproducible results.

PIK3CG’s Dual Roles in Septic Myocardial Injury:

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to advancing life science research and clinical diagnostics by providing high-performance, innovative core reagents and comprehensive solutions. Leveraging advanced development platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development platforms (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—the company adheres to stringent quality standards and has successfully obtained EU 98/79/EC certification, ISO9001 certification, and ISO13485 certification. ANT BIO PTE. LTD. strives to support researchers and clinicians worldwide in their pursuit of scientific breakthroughs, improved patient care, and the development of innovative therapies for sepsis and cardiovascular diseases.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.